Impact of Palmitoylethanolamide (PEA) in the Management of Oro-facial Pain
Status:
Recruiting
Trial end date:
2023-08-17
Target enrollment:
Participant gender:
Summary
Pain is the most common symptom faced by dentists, whether acute (pulpitis, acute
periodontitis, post-surgical, etc.) or chronic (chronic periodontitis, muscle pain, TMJ
disorders, BMS, OLP, etc.). The success of therapy depends on the reduction and management of
pain. Therefore, over the past few years, the need has emerged, also in relation to the aging
population, to analyze new molecules with pain-relieving activity and with low risk of
inducing side effects and interactions with other drugs; capable of bringing about the
reduction of oro-facial pain; and that lend themselves to prolonged use.
Palmitoylethanolamide (PEA) is a bioactive lipid mediator similar to endocannabinoids (eCBs)
that has been observed to have anti-inflammatory, analgesic, anticonvulsant, antimicrobial,
antipyretic, antiepileptic, immunomodulatory, and neuroprotective activities.
The objective is to clinically study, through a clinical trial, the pain-relieving and
anti-inflammatory properties of a PEA-containing nutraceutical agent in the management of
patients with orofacial pain, both neuropathic and nociceptive in nature.